Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
22 current organizations shown on this profile
Board positions
22 supported by public sources, 0 supplied by the profile owner
Committee roles
4Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Most recently served as Chief Executive Officer of Valeritas from 2009 to 2016. Previously held senior executive roles at Johnson & Johnson and Biovail Corporation. Spent 20 years at Bristol-Myers Squibb in senior roles across multiple disease areas. Currently serves on boards of ArriVent BioPharma and Enanta Pharmaceuticals.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

ArriVent BioPharma, Inc.

2024-01-01 · current

Confirmed by public sourceView source

Director

Immunocore Holdings plc

2017-01-01 · current

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

ArriVent BioPharma, Inc.

Open ArriVent BioPharma, Inc. profile →

Director at ArriVent BioPharma, Inc.

2024-01-01 → End not stated

current · source reported

Observed: 2026-09-25

ArriVent BioPharma…ArriVent BioPharma, Inc.Immunocore Holding…Immunocore Holdings plcKristine Peterson

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingIMCR DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Cybersecurity experience, Technology background.Open sourceSource 2 · Sec FilingAVBP DEF 14A director slateSupports Board role, Committee assignments.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:kristine-peterson
Record version
public-0

Published evidence records

6 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. IMCR DEF 14A director slate

    sec filing · Source published: Apr 16, 2026 · Retrieved: May 16, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Remuneration, Nominating/Governance · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. Open source

    sec proxy · Source published: Apr 16, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Immunocore Holdings plc · Claim reviewed: May 16, 2026

  3. AVBP DEF 14A director slate

    sec filing · Source published: Apr 28, 2025 · Retrieved: May 15, 2026

    Supports 2 claims
    • Board role: Board role: Lead Independent Director · Claim reviewed: May 15, 2026
    • Committee assignments: Committee assignments: Audit, Compensation · Claim reviewed: May 15, 2026

  4. Open source

    sec proxy · Source published: Apr 28, 2025 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at ArriVent BioPharma, Inc. · Claim reviewed: May 16, 2026

  5. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of ArriVent BioPharma, Inc. · Claim reviewed: May 16, 2026

  6. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Immunocore Holdings plc · Claim reviewed: May 16, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · Source reportedAI and ML experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board membership · Source reportedServes on the board of ArriVent BioPharma, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Immunocore Holdings plc1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · Source reportedBoard role: Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Board role · Source reportedBoard role: Lead Independent Director1 source
Verification
Source reported
Confidence
92%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Audit, Compensation1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 15, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

Committee assignments · Source reportedCommittee assignments: Remuneration, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · Source reportedCybersecurity experience: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Technology background · Source reportedTechnology background: not identified in the cited filing1 source
Verification
Source reported
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources6 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Cybersecurity experience · Technology background

  2. https://www.sec.gov/Archives/edgar/data/1671927/000114036126015122/ny20070395x1_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Immunocore Holdings plc (NASDAQ: IMCR)

  3. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 15, 2026

    Supports: Board role · Committee assignments

  4. https://www.sec.gov/Archives/edgar/data/1868279/000110465925040214/tm2513051-2_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at ArriVent BioPharma, Inc. (NASDAQ: AVBP)

  5. https://www.sec.gov/Archives/edgar/data/1868279/000110465925040214/tm2513051-2_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  6. https://www.sec.gov/Archives/edgar/data/1671927/000114036126015122/ny20070395x1_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership